Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 38Lymphoma, Follicular 14Lymphoma, Non-Hodgkin 9Waldenstrom Macroglobulinemia 8Lymphoma, B-Cell, Marginal Zone 7Lymphoma, Mantle-Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell 4Lymphoma 4Leukemia, Myeloid, Acute 4Leukemia 4Lymphoma, Large B-Cell, Diffuse 3Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, B-Cell 2Hodgkin Disease 2Thrombocytosis 1Signs and Symptoms, Digestive 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

zanubrutinib 3tislelizumab 1tirabrutinib 1obinutuzumab 1itacitinib 1idelalisib 1Voriconazole 1Influenza Vaccines 1INCB039110 1Fluconazole 1Diltiazem 1Clarithromycin 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
B-cell Malignancies × idelalisib × Lymphoid × Clear all
NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Gilead Sciences

Phase 1 Terminated
203 enrolled 43 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡